Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96L21

UPID:
RL10L_HUMAN

ALTERNATIVE NAMES:
60S ribosomal protein L10-like; Large ribosomal subunit protein uL16-like

ALTERNATIVE UPACC:
Q96L21; Q8IUD1

BACKGROUND:
The Ribosomal protein uL16-like, alternatively named Large ribosomal subunit protein uL16-like, is integral to the ribosome's function in the cell, specifically in the synthesis of proteins. It is uniquely involved in male germ cell development, facilitating the transition crucial stages in meiosis and compensating for certain inactivated paralogs during spermatogenesis. Its distinct ribosomal exit tunnel plays a vital role in the specific biosynthesis and proper folding of proteins necessary for sperm development.

THERAPEUTIC SIGNIFICANCE:
Ribosomal protein uL16-like's involvement in Spermatogenic failure 63 highlights its potential as a target for therapeutic intervention in male infertility. The protein's unique function in spermatogenesis suggests that enhancing our understanding of its role could lead to innovative treatments for infertility disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.